See more : Schaeffler AG (SCFLF) Income Statement Analysis – Financial Results
Complete financial analysis of PTC Therapeutics, Inc. (PTCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PTC Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK) Income Statement Analysis – Financial Results
- Western Acquisition Ventures Corp. (WAVS) Income Statement Analysis – Financial Results
- MediPharm Labs Corp. (MEDIF) Income Statement Analysis – Financial Results
- OncoTherapy Science, Inc. (4564.T) Income Statement Analysis – Financial Results
- Ubiqconn Technology, Inc. (6928.TW) Income Statement Analysis – Financial Results
PTC Therapeutics, Inc. (PTCT)
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 937.82M | 698.80M | 538.59M | 380.77M | 306.98M | 264.73M | 194.39M | 82.71M | 36.77M | 22.96M | 31.33M | 28.78M | 98.96M |
| Cost of Revenue | 65.49M | 44.68M | 32.33M | 18.94M | 12.14M | 12.67M | 4.58M | 117.63M | 121.82M | 79.84M | 54.88M | -5.17M | 0.00 |
| Gross Profit | 872.34M | 654.12M | 506.27M | 361.82M | 294.85M | 252.06M | 189.82M | -34.93M | -85.05M | -56.88M | -23.55M | 33.95M | 98.96M |
| Gross Profit Ratio | 93.02% | 93.61% | 94.00% | 95.03% | 96.05% | 95.21% | 97.65% | -42.23% | -231.33% | -247.68% | -75.17% | 117.95% | 100.00% |
| Research & Development | 666.56M | 651.50M | 540.68M | 477.64M | 257.45M | 171.98M | 117.46M | 117.63M | 121.82M | 79.84M | 54.88M | 46.14M | 58.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 332.54M | 326.00M | 285.77M | 245.16M | 202.54M | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Other Expenses | 0.00 | 116.55M | 54.75M | 36.89M | 27.65M | 129.00K | -1.28M | -1.21M | -465.00K | -213.00K | 37.51K | 1.78M | 461.36K |
| Operating Expenses | 1.31B | 1.09B | 881.21M | 759.70M | 487.64M | 348.41M | 254.11M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Cost & Expenses | 1.29B | 1.14B | 913.54M | 778.64M | 499.78M | 361.08M | 258.68M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Interest Income | 0.00 | 90.87M | 86.02M | 56.35M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 129.18M | 90.87M | 86.02M | 56.35M | 12.49M | 12.55M | 12.09M | 8.28M | 2.37M | 1.18M | 0.00 | 0.00 | 2.44M |
| Depreciation & Amortization | 236.59M | 128.84M | 71.52M | 49.58M | 36.06M | 26.09M | 17.68M | 3.29M | 2.88M | 2.24M | 2.40M | 2.70M | 2.87M |
| EBITDA | -330.34M | -367.78M | -374.44M | -297.00M | -191.38M | -89.47M | -46.61M | -128.77M | -164.25M | -97.18M | -43.00M | -24.10M | 33.45M |
| EBITDA Ratio | -35.22% | -53.32% | -70.20% | -59.83% | -38.04% | -20.45% | -25.16% | -159.67% | -454.58% | -432.93% | -136.85% | -83.76% | 33.80% |
| Operating Income | -349.40M | -439.93M | -374.94M | -397.88M | -192.80M | -115.69M | -64.29M | -132.06M | -167.13M | -99.41M | -45.40M | -26.81M | 30.58M |
| Operating Income Ratio | -37.26% | -62.95% | -69.62% | -104.49% | -62.80% | -43.70% | -33.07% | -159.67% | -454.58% | -432.93% | -144.92% | -93.15% | 30.90% |
| Total Other Income/Expenses | -346.71M | -147.56M | -143.40M | -59.36M | -47.13M | -12.43M | -13.37M | -9.48M | -2.83M | 967.00K | -6.18M | 573.00K | -1.98M |
| Income Before Tax | -696.11M | -587.49M | -518.34M | -402.93M | -239.93M | -128.11M | -77.67M | -141.54M | -169.96M | -98.45M | -51.57M | -26.24M | 28.60M |
| Income Before Tax Ratio | -74.23% | -84.07% | -96.24% | -105.82% | -78.16% | -48.39% | -39.95% | -171.14% | -462.28% | -428.72% | -164.63% | -91.16% | 28.90% |
| Income Tax Expense | -69.51M | -28.47M | 5.56M | 35.23M | 11.65M | -29.00K | 1.34M | 569.00K | 485.00K | -4.69M | 6.21M | 1.21M | -2.31M |
| Net Income | -626.60M | -559.02M | -523.90M | -438.16M | -251.58M | -128.08M | -79.00M | -142.11M | -170.45M | -93.75M | -51.57M | -26.24M | 30.90M |
| Net Income Ratio | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.60% | -408.28% | -164.63% | -91.16% | 31.23% |
| EPS | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.85 | 0.00 |
| EPS Diluted | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.11 | 0.00 |
| Weighted Avg Shares Out | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.11M | 34.04M | 33.62M | 31.57M | 12.82M | 14.19M | 14.19M |
| Weighted Avg Shares Out (Dil) | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 23.68M | 23.68M |
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCT
Source: https://incomestatements.info
Category: Stock Reports